Mga Batayang Estadistika
| LEI | 9845000861BC95FF9F73 |
| CIK | 1703057 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AbCellera Biologics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| August 7, 2025 |
NEWS RELEASE AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms 8/7/2025 VANCOUVER, British Columbia-(BUSINESS WIRE)- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. |
|
| August 7, 2025 |
abcl2025q2businessupdate CO PY RI GH T © A BC EL LE RA August 7, 2025 Q2 2025 BUSINESS UPDATE These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2025 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2025 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| May 30, 2025 |
a8k2025-05x30abclexhibit AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 ● ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis ● AbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in Q3 2025 VANCOUVER, British Columbia– AbCellera (Nasdaq: |
|
| May 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2025 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| May 14, 2025 |
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause AbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 VANCOUVER, British Columbia– AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor (NK3R) that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| May 13, 2025 |
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit The Federal Circuit rejects Bruker Cellular’s invalidity challenge to AbCellera’s patent for microfluidic devices and their use in culturing cells VANCOUVER, British Columbia, May 12, 2025 - AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) (C |
|
| May 8, 2025 |
CO PY RI GH T © A BC EL LE RA MAY 8, 2025 Q1 2025 BUSINESS UPDATE These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| May 8, 2025 |
NEWS RELEASE AbCellera Reports Q1 2025 Business Results 5/8/2025 VANCOUVER, British Columbia-(BUSINESS WIRE)- AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| February 27, 2025 |
Calculation of Filing Fee Tables S-8 AbCellera Biologics Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Shares, no par value per share Other 14,787,850 $ 2.92 $ 43,180,522.00 0.0001531 $ 6,610.94 Total Off |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Abcellera Biologics Inc. |
|
| February 27, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of AbCellera Biologics Inc.* Name Jurisdiction of Incorporation or Organization AbCellera Australia Pty Ltd. Australia AbCellera Boston Inc. New York AbCellera Properties LP. Canada AbCellera Properties Columbia LP. Canada AbCellera Properties Evans LP. Canada AbCellera US Holdings Inc. Delaware Biologiques AbCellera Quebec Inc. Canada Lineage Biosciences Inc. Delaware Tr |
|
| February 27, 2025 |
Power of Attorney (included on the signature page hereto) As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 AbCellera Biolo |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Exhibit 4.2 ABCELLERA BIOLOGICS INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| February 27, 2025 |
Form of Subordinated Indenture Exhibit 4.3 ABCELLERA BIOLOGICS INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certif |
|
| February 27, 2025 |
NEWS RELEASE AbCellera Reports Full Year 2024 Business Results 2/27/2025 VANCOUVER, British Columbia-(BUSINESS WIRE)- AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. |
|
| February 27, 2025 |
Insider Trading Compliance Policy ACTIVE/105361688.4 ABCELLERA BIOLOGICS INC. INSIDER TRADING COMPLIANCE POLICY AbCellera Biologics Inc., a company incorporated under the Business Corporations Act (British Columbia) (together with its subsidiaries, the “Company”) prohibits: • insider trading in the Company’s securities or shares (collectively, “Securities”); and • the unauthorized disclosure of the Company’s confidential informati |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2025 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporati |
|
| February 27, 2025 |
CO PY RI GH T © A BC EL LE RA FEBRUARY 27, 2025 FULL YEAR 2024 BUSINESS UPDATE These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2025 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporati |
|
| November 14, 2024 |
ABCL / AbCellera Biologics Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| November 4, 2024 |
CO PY RI GH T © A BC EL LE RA NOVEMBER 4, 2024 Q3 2024 BUSINESS UPDATE These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2024 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporatio |
|
| November 4, 2024 |
NEWS RELEASE AbCellera Reports Q3 2024 Business Results 11/04/2024 VANCOUVER, British Columbia - AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2024. |
|
| August 6, 2024 |
q2248kearningsdeckfinal C O P Y R IG H T © A B C E LL E R A Q2 2024 BUSINESS UPDATE AUGUST 6, 2024 C O PY R IG H T © A B C EL LE R A DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| August 6, 2024 |
NEWS RELEASE AbCellera Reports Q2 2024 Business Results 08/06/2024 VANCOUVER, British Columbia - AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| August 6, 2024 |
2020 Share Option and Incentive Plan and forms of award agreements thereunder ( ABCELLERA BIOLOGICS INC. 2020 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the AbCellera Biologics Inc. 2020 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of AbCellera Biologics Inc. (the “Company”) and its Affiliates upon |
|
| August 6, 2024 |
ABCELLERA BIOLOGICS INC. SEVENTH AMENDED AND RESTATED STOCK OPTION PLAN Approved by the Board of Directors on April 30, 2024. Exhibit 10.1 i TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND INTERPRETATION ...............................................................1 1.1 Definitions................................................................................................................1 1.2 Ch |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2024 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| May 7, 2024 |
abcelleraq12024businessu C O P YR IG H T © A B C E LL E R A Q1 2024 BUSINESS UPDATE MAY 7, 2024 C O PY RI G H T © A B C EL LE RA DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| May 7, 2024 |
NEWS RELEASE AbCellera Reports Q1 2024 Business Results 05/07/2024 VANCOUVER, British Columbia-(BUSINESS WIRE) - AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) (C |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| February 23, 2024 |
NEWS RELEASE AbCellera Announces Resignation of Board Member 02/23/2024 VANCOUVER, British Columbia, February 23, 2024 – AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024. |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2024 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporati |
|
| February 20, 2024 |
NEWS RELEASE AbCellera Reports Full Year 2023 Business Results 2/20/2024 ●Total revenue of $38 million, compared to $485 million in FY 2022 ●Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year ●Net loss of $0. |
|
| February 20, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) AbCellera Biologics Inc. |
|
| February 20, 2024 |
1 CONTRIBUTION AGREEMENT (Project Peregrine) This Agreement made Between: HIS MAJESTY THE KING IN RIGHT OF THE PROVINCE OF BRITISH COLUMBIA, as represented by the Ministry of Jobs, Economic Development and Innovation (the “Province”) And: ABCELLERA BIOLOGICS INC. |
|
| February 20, 2024 |
AbCellera Biologics Inc. Compensation Clawback Policy. ABCELLERA BIOLOGICS INC. COMPENSATION RECOVERY POLICY Adopted as of November 30, 2023 AbCellera Biologics Inc. (the “Company”) has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance wi |
|
| February 20, 2024 |
As filed with the Securities and Exchange Commission on February 20, 2024 As filed with the Securities and Exchange Commission on February 20, 2024 Registration No. |
|
| February 20, 2024 |
SIF AGREEMENT NO. 813-819720 STRATEGIC INNOVATION FUND Project Peregrine This Agreement made Between: And: RECITALS WHEREAS HIS MAJESTY THE KING IN RIGHT OF CANADA ("His Majesty") as represented by the Minister of Industry (the "Minister") AbCellera Biologics Inc., a corporation duly incorporated under the laws of British Columbia, having its head office located at 2215 Yukon Street, Vancouver, Br |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2024 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporati |
|
| February 20, 2024 |
abcelleraq4fy2023busines C O P YR IG H T © A B C E LL E R A FULL YEAR 2023 BUSINESS UPDATE FEBRUARY 20, 2024 C O PY RI G H T © A B C EL LE RA DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 AbCellera Biolo |
|
| February 20, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of AbCellera Biologics Inc.* Name Jurisdiction of Incorporation or Organization AbCellera Australia Pty Ltd. Australia AbCellera Biologics UK Ltd. United Kingdom AbCellera Boston Inc. New York AbCellera Properties Inc. Canada AbCellera Properties Columbia Inc. Canada AbCellera Properties Evans Inc. Canada AbCellera US Holdings Inc. Delaware Biologiques AbCellera Quebec In |
|
| February 14, 2024 |
ABCL / AbCellera Biologics Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SC 13G 1 tm242424d5sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* AbCellera Biologics Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 00288U106 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2024 |
EX-99.1 2 tm242424d5ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Shares of AbCellera Biologics Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2024 BAKER BROS. ADV |
|
| February 13, 2024 |
ABCL / AbCellera Biologics Inc. / Hansen Carl L. G. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* AbCellera Biologics Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 00288U 10 6 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 28, 2023 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporati |
|
| November 2, 2023 |
Certain information in this document has been omitted from this exhibit because it is (i) not material (ii) would be competitively harmful if publicly disclosed and (iii) private or confidential. |
|
| November 2, 2023 |
abcelleraq32023businessu C O P Y R IG H T © A B C E LL E R A Q3 2023 BUSINESS UPDATE NOVEMBER 2, 2023 C O PY RI G H T © A B C EL LE RA DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| November 2, 2023 |
q32023earningspressrelea NEWS RELEASE AbCellera Reports Q3 2023 Business Results 11/02/2023 ● Total revenue of $7 million, compared to $101 million in Q3 2022 ● Total cumulative partnered program starts of 110, up 20% from Q3 2022 ● Net loss of $0. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporatio |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 18, 2023 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporat |
|
| August 3, 2023 |
abcellerabccontributiona 1 CONTRIBUTION AGREEMENT (Project Peregrine) This Agreement made Between: HIS MAJESTY THE KING IN RIGHT OF THE PROVINCE OF BRITISH COLUMBIA, as represented by the Ministry of Jobs, Economic Development and Innovation (the “Province”) And: ABCELLERA BIOLOGICS INC. |
|
| August 3, 2023 |
NEWS RELEASE AbCellera Reports Q2 2023 Business Results 08/03/2023 ●Total revenue of $10 million, compared to $46 million in Q2 2022 ●Total cumulative partnered program starts of 106, up 20% from Q2 2022 ●Net loss of $0. |
|
| August 3, 2023 |
abcelleraq22023businessu CO PY RI GH T © A BC EL LE RA Q2 2023 BUSINESS UPDATE AUGUST 3, 2023 CO PY RI GH T © A BC EL LE RA DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2023 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| August 3, 2023 |
abcellera813-8197inalcon o : |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2023 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 24, 2023 |
a991prexhibit 1 NEWS RELEASE AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients MAY 24, 2023 • CA$701 million co-investment to strengthen capabilities and infrastructure for drug development, manufacturing, and clinical research in Canada • AbCellera to build state- |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2023 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| May 4, 2023 |
q12023earningspressrelea NEWS RELEASE 1 AbCellera Reports Q1 2023 Business Results 05/04/2023 ● Total revenue of $12 million, compared to $317 million in Q1 2022 ● Total cumulative partnered program starts of 101, up 20% from Q1 2022 ● Net loss of $0. |
|
| May 4, 2023 |
abcelleraq12023businessu Ql 2023 BUSINESS UPDATE § MAY4,2023 u = :::c co = > o. D u (3cellera cm••-... -• .. - .,..,. ., -· -··-·-, .. , -~· -·,-•-1-•· .. ... - -·- .., -.,'- - , ,. -·-·-•-■ .. - T-cell engagers with optimal functional properties - - -·-· - .. -·- ·-~- ,. -·-···-~-.. -=s=====~-=-..:.:...-=-===•==-:=::-=-=-...::. ,~LLJ:, I - I • • I . ... '. - -;;;;:-i;;-, , -,=====,-•au,1111■-•-ll |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) (C |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Con |
|
| April 24, 2023 |
ABCL / AbCellera Biologics Inc / THIEL PETER - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* AbCellera Biologics Inc. (Name of Issuer) Common shares, no par value per share (Title of Class of Securities) 00288U 10 6 (CUSIP Number) David Wheelock General Counsel Thiel Capital LLC 9200 Sunset Boulevard, Suite 1110 West Hollywood, CA 90069 323-990- |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2023 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporati |
|
| February 21, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Abcellera Biologics Inc. |
|
| February 21, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of AbCellera Biologics Inc.* Name Jurisdiction of Incorporation or Organization AbCellera Australia Pty Ltd. Australia AbCellera Biologics UK Ltd. United Kingdom AbCellera Boston, Inc. New York AbCellera Properties Inc. Canada AbCellera Properties Columbia Inc. Canada AbCellera Properties Evans Inc. Canada AbCellera US, Inc. Delaware Biologiques AbCellera Québec Inc. Cana |
|
| February 21, 2023 |
AbCellera FULL YEAR 2022 BUSINESS UPDATE FEBRUARY 21,2023 COPYRIGHT © ABCELLERA Exhibit 99. |
|
| February 21, 2023 |
Exhibit 99.1 NEWS RELEASE AbCellera Reports Full Year 2022 Business Results 02/21/2023 • Total revenue of $485 million, compared to $375 million in FY 2021 • Total cumulative partnered program starts of 101, with 23 new starts in the year • Net earnings of $0.56 per share on a basic and $0.50 on a diluted basis, compared to earnings of $0.56 (basic) and $0.48 (diluted) per share in 2021 VANCOUVER, |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K lll UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 AbCellera B |
|
| February 21, 2023 |
As filed with the Securities and Exchange Commission on February 21, 2023 As filed with the Securities and Exchange Commission on February 21, 2023 Registration No. |
|
| February 13, 2023 |
ABCL / AbCellera Biologics Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* AbCellera Biologics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00288U106 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 6, 2023 |
ABCL / AbCellera Biologics Inc / Hansen Carl L. G. - SC 13G/A Passive Investment SC 13G/A 1 d409918dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* AbCellera Biologics Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 00288U 10 6 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Che |
|
| November 8, 2022 |
Exhibit 99.1 NEWS RELEASE AbCellera Reports Q3 2022 Business Results 11/08/2022 • Total revenue of $101 million, compared to $6 million in Q3 2021 • Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 • Net earnings of $0.09 per share on a basic and $0.08 on a diluted basis, compared to a net loss of ($0.08) per share (basic and diluted) in Q3 2021 VANCOUVER, B |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporatio |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| November 8, 2022 |
Exhibit 99.2 rAblellera Q3 2022 BUSINESS UPDATE NOVEMBER 8, 2022 Exhibit 99.2 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| August 9, 2022 |
Exhibit 99.2 AbCellera Q2 2022 BUSINESS UPDATE AUGUST 9, 2022 COPYRIGHT ABCELLERA DISCLAIMER Q2 2022 BUSINESS UPDATE This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information curren |
|
| August 9, 2022 |
NEWS RELEASE Exhibit 99.1 AbCellera Reports Q2 2022 Business Results 08/09/2022 ? Total revenue of $46 million, compared to $28 million in Q2 2021 ? Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021 ? Net loss of ($0.02) per share on a basic and diluted basis compared to ($0.01) (basic and diluted) per share in Q2 2021 VANCOUVER, British Columbia, August 9, 20 |
|
| July 22, 2022 |
CORRESP 1 filename1.htm July 22, 2022 VIA EDGAR AND FEDERAL EXPRESS Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Tara Harkins Daniel Gordon Re: AbCellera Biologics Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 25, 2022 File No. 001-39781 Dear Ms. Harkins and Mr. Go |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-397 |
|
| July 19, 2022 |
DocuSign Envelope ID: F7DBC1FF-65F5-4693-B92E-A83AF74A5718 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Neil Berkley (?Employee?) and Lineage Biosciences, Inc. |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| July 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| June 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| June 30, 2022 |
Exhibit 99.1 NEWS RELEASE Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options 06/29/2022 Bebtelovimab continues to maintain neutralization activity against all known variants of interest and concern VANCOUVER, British Columbia, June 29, 2022 ? AbCellera (Nasdaq: ABCL) today announ |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| May 10, 2022 |
Exhibit 99.1 NEWS RELEASE AbCellera Reports Q1 2022 Business Results 05/10/2022 ? Total revenue of $317 million, compared to $203 million in Q1 2021 ? Six program starts in the quarter bringing cumulative total to 84, up 56% from Q1 2021 ? Net earnings of $0.59 per share on a basic and $0.54 on a diluted basis compared to $0.43 (basic) and $0.37 (diluted) per share in Q1 2021 VANCOUVER, British Co |
|
| May 10, 2022 |
Exhibit 99.2 Exhibit 99.2 AbCellera Q1 2022 BUSINESS UPDATE MAY 10, 2022 COPYRIGHT ? ABCELLERA 2 DISCLAIMER This presentation contains forward- looking statements including statement made pursuant to the safe harbor provisions of the private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management. All statements contained in this presentation other than sta |
|
| April 28, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use o |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 AbCellera Biolo |
|
| February 25, 2022 |
As filed with the Securities and Exchange Commission on February 25, 2022 POS AM 1 ny20001536x2posam.htm POS AM TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 25, 2022 Registration No. 333-256998 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 ON FORM S-3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ABCELLERA BIOLOGICS INC. (Exact Name of Registrant as Speci |
|
| February 25, 2022 |
Exhibit 99.4 INDEPENDENT AUDITOR?S REPORT Board of Directors Trianni, Inc. San Francisco, California We have audited the accompanying financial statements of Trianni, Inc. (a California corporation) (the ?Company?), which comprise the balance sheets as of December 31, 2018 and 2019, and the related statements of operations, convertible preferred stock and stockholders? equity, and cash flows for t |
|
| February 25, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION In November 2020, we entered into the merger agreement with Trianni, under which, at the effective time, our wholly owned entity, or Merger Sub, merged with and into Trianni, with Trianni surviving as our wholly owned subsidiary. Pursuant to the merger agreement, each share of Trianni convertible preferred stock was converte |
|
| February 25, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Abcellera Biologics Inc. |
|
| February 25, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Abcellera Biologics Inc. |
|
| February 25, 2022 |
ABCELLERA BIOLOGICS INC. Dated as of [●] Senior Debt Securities TABLE OF CONTENTS Exhibit 4.3 ABCELLERA BIOLOGICS INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate 7 |
|
| February 25, 2022 |
As filed with the Securities and Exchange Commission on February 25, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 25, 2022 Registration No. |
|
| February 25, 2022 |
ABCELLERA BIOLOGICS INC. Dated as of [●] Subordinated Debt Securities TABLE OF CONTENTS Exhibit 4.4 ABCELLERA BIOLOGICS INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certific |
|
| February 25, 2022 |
As filed with the Securities and Exchange Commission on February 25, 2022 As filed with the Securities and Exchange Commission on February 25, 2022 Registration No. |
|
| February 24, 2022 | ||
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporati |
|
| February 24, 2022 |
Exhibit 99.1 NEWS RELEASE AbCellera Reports Full Year 2021 Business Results 02/24/2022 ? Total revenue of $375 million, up from $233 million in 2020, and liquidity of over $720 million ? Total cumulative program starts of 78, with 26 new starts in the year ? EPS of $0.56 (basic) and $0.48 (diluted) compared to $0.53 (basic) and $0.45 (diluted) per share in 2020 VANCOUVER, British Columbia, Februar |
|
| February 16, 2022 |
AbCellera Biologics Inc. 12,000,000 Common Shares 424B3 1 abcl-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 10 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 10 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the |
|
| February 15, 2022 |
Exhibit 99.1 NEWS RELEASE AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 2/11/2022 ? Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data ? Previously reported data show that bebtelovimab has broad and potent neutralization o |
|
| February 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2022 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporati |
|
| February 14, 2022 |
ABCL / AbCellera Biologics Inc / DCVC Bio, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1) * AbCellera Biologics Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 00288U106 (CUSIP Number) December 31, 2021 (Date of Event W |
|
| February 14, 2022 |
ABCL / AbCellera Biologics Inc / VIKING GLOBAL INVESTORS LP - SC 13GA Passive Investment SC 13G/A 1 brhc10033254sc13ga.htm SC 13GA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* AbCellera Biologics Inc. (Name of Issuer) Common stock, no par value per share (Title |
|
| February 11, 2022 |
ABCL / AbCellera Biologics Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AbCellera Biologics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00288U106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 10, 2022 |
ABCL / AbCellera Biologics Inc / Hansen Carl L. G. - SC 13G/A Passive Investment SC 13G/A 1 d257192dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* AbCellera Biologics Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 00288U 10 6 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Che |
|
| December 7, 2021 |
AbCellera Announces Changes to Its Board of Directors Exhibit 99.1 NEWS RELEASE AbCellera Announces Changes to Its Board of Directors 12/7/2021 VANCOUVER, British Columbia, December 7, 2021 ? AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignati |
|
| December 7, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares 424B3 1 abcl-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 9 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 9 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the se |
|
| December 7, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares 424B3 1 abcl-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 8 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 8 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the se |
|
| December 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporatio |
|
| December 3, 2021 |
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer Exhibit 99.1 NEWS RELEASE AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer 12/02/2021 VANCOUVER, British Columbia, December 2, 2021 ? AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 |
|
| December 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporatio |
|
| November 12, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares 424B3 1 abcl-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 7 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 7 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the se |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporatio |
|
| November 9, 2021 |
Exhibit 99.1 NEWS RELEASE AbCellera Reports Q3 2021 Business Results 11/09/2021 ? Total revenue of $6 million, compared to $9 million in Q3 2020 ? Nine program starts in the quarter bringing cumulative total to 69, up 35% from Q3 2020 ? Net loss of ($0.08) per share (basic and diluted) compared to a net loss of ($0.02) per share (basic and diluted) in Q3 2020 VANCOUVER, British Columbia, November |
|
| November 9, 2021 |
Q3 2021 Business Update NOV 9, 2021 Q3 2021 Business Update NOV 9, 2021 DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| November 4, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares 424B3 1 abcl-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 6 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 6 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the se |
|
| November 4, 2021 |
Exhibit 99.1 NEWS RELEASE Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19 11/02/2021 VANCOUVER, British Columbia ? AbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etese |
|
| November 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporatio |
|
| September 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporat |
|
| September 23, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 5 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 5 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the selling shareholders identified |
|
| September 23, 2021 |
EX-99.1 2 abcl-ex99124.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 09/21/2021 ● Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently the cause of over 95 percent of new COVID-19 infections in the EU/EEA ● Participating EU/E |
|
| September 15, 2021 |
Exhibit 99.1 NEWS RELEASE AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets 09/13/2021 Acquisition expands AbCellera?s existing capabilities to unlock difficult-to-drug transmembrane proteins for antibody discovery programs VANCOUVER, British Columbia & BOSTON, September 13, 2021 ? AbCellera (Nasdaq: ABCL), a technology company with a centra |
|
| September 15, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 4 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 4 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the selling shareholders identified |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporat |
|
| August 17, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 3 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 1 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the selling shareholders identified |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation |
|
| August 12, 2021 |
Exhibit 99.1 NEWS RELEASE AbCellera Reports Q2 2021 Business Results 08/12/2021 ? Total revenue of $28 million, up from $11 million in Q2 2020 ? Total programs under contract of 138, up 82% from Q2 2020 ? Net loss of ($0.01) per share (basic and diluted) compared to net earnings of $0.03 per share (basic and diluted) in Q2 2020 VANCOUVER, British Columbia, August 12, 2021 - AbCellera (Nasdaq: ABCL |
|
| August 12, 2021 |
Q2 2021 Business Update AUG 12, 2021 Q2 2021 Business Update AUG 12, 2021 DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| July 15, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares 424B3 1 abcl-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 2 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the se |
|
| July 13, 2021 |
Financial Statements and Exhibits 8-K 1 abcl-8k20210713.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 13, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other j |
|
| July 13, 2021 |
AbCellera Appoints Neil Berkley as Chief Business Officer Exhibit 99.1 NEWS RELEASE AbCellera Appoints Neil Berkley as Chief Business Officer 07/13/2021 VANCOUVER, British Columbia? AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Business Officer (CBO). Mr. Berkley?s role will include leading the strategy and continued |
|
| June 25, 2021 |
AbCellera Biologics Inc. 12,000,000 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus Dated June 21, 2021) AbCellera Biologics Inc. 12,000,000 Common Shares This prospectus supplement no. 1 supplements the prospectus dated June 21, 2021, relating to the offering and resale of up to 12,000,000 common shares, no par value per share, to be sold by the selling shareholders identified |
|
| June 22, 2021 |
12,000,000 Common Shares ABCELLERA BIOLOGICS INC. Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-256998 PROSPECTUS 12,000,000 Common Shares ABCELLERA BIOLOGICS INC. This prospectus relates to the offer and sale of up to 12,000,000 common shares, no par value, of AbCellera Biologics Inc., a British Columbia corporation, by the selling shareholders. The common shares being offered by the selling shareholders were purchased |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| June 17, 2021 |
VIA EDGAR June 17, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4561 100 F Street, N. |
|
| June 10, 2021 |
As filed with the Securities and Exchange Commission on June 10, 2021 Table of Contents As filed with the Securities and Exchange Commission on June 10, 2021 Registration No. |
|
| May 17, 2021 |
May 13, 2021 Q1 2021 BUSINESS UPDATE May 13, 2021 Q1 2021 BUSINESS UPDATE This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| May 17, 2021 |
AbCellera Reports Q1 2021 Business Results Exhibit 99.1a AbCellera Reports Q1 2021 Business Results ? Total revenue of $203 million, up from $5 million in Q1 2020 ? Total programs under contract of 119, up 63% year-over-year ? EPS of $0.43 (basic) and $0.37 (diluted) compared to $0.01 loss per share in Q1 2020 VANCOUVER, British Columbia, May 13, 2021 - AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2021 (May 13, 2021) ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39781 AbCellera Biologics Inc. |
|
| May 13, 2021 |
AbCellera Reports Q1 2021 Business Results EX-99.1 2 abcl-ex9917.htm EX-99.1 Exhibit 99.1 AbCellera Reports Q1 2021 Business Results ● Total revenue of $203 million, up from $5 million in Q1 2020 ● Total programs under contract of 119, up 63% year-over-year ● EPS of $0.43 (basic) and $0.37 (diluted) compared to $0.01 loss per share in Q1 2020 VANCOUVER, British Columbia, May 13, 2021 - AbCellera (Nasdaq: ABCL), a technology company with a |
|
| May 13, 2021 |
8-K 1 abcl-8k20210513.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other ju |
|
| May 13, 2021 |
May 13, 2021 Q1 2021 BUSINESS UPDATE May 13, 2021 Q1 2021 BUSINESS UPDATE This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use o |
|
| April 28, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? |
|
| April 1, 2021 |
EX-99.1 Exhibit 99.1 AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera’s entire technology stack, including the Trianni Mouse® and the OrthoMab™ bispecific platforms VANCOUVER, British Columbia, April 1, 2021 – AbCellera (Nasdaq: ABCL) today announced agreem |
|
| April 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| March 30, 2021 |
Exhibit 4.3 DESCRIPTION OF SECURITIES As of December 31, 2020, AbCellera Biologics, Inc. (the ?Company,? ?we,? ?us,? and ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Shares. Description of Common Shares The following description of our Common Shares is a summary and does not purport to be complete. It is subject to an |
|
| March 30, 2021 |
Exhibit 3.1 TABLE OF CONTENTS BUSINESS CORPORATIONS ACT ARTICLES of ABCELLERA BIOLOGICS INC. Page ARTICLE 1 INTERPRETATION 1.1 Definitions 1 1.2 Business Corporations Act and Interpretation Act Definitions Applicable 1 ARTICLE 2 SHARES AND SHARE CERTIFICATES 2.1 Authorized Share Structure 2 2.2 Form of Share Certificate 2 2.3 Shareholder Entitled to Certificate or Acknowledgement 2 2.4 Delivery by |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 AbCellera Biolo |
|
| March 29, 2021 |
March 29, 2021 2020 BUSINESS UPDATE Exhibit 99.2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management?s beliefs and assumptions and on information currently available to management. All statements contained in this presen |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39781 Not Applicable (State or other jurisdiction of incorporation) |
|
| March 29, 2021 |
AbCellera Reports Full Year 2020 Business Results Exhibit 99.1 AbCellera Reports Full Year 2020 Business Results ● Total revenue of $233 million1 in 2020, up 1,908% year-over-year ● Total revenue from research fees of $20 million, up 71% year-over-year ● Total programs under contract of 103, up 72% year-over-year ● EPS of $0.53 (basic) and $0.45 (diluted) compared to $0.01 loss per share in 2019 VANCOUVER, British Columbia - March 29, 2021 - AbCe |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 ABCELLERA BIOLOGICS INC. (Exact name of registrant as specified in its charter) British Columbia 001 - 39781 Not Applicable (State or other jurisdiction of incorpora |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* AbCellera Biologics Inc. (Name of Issuer) Common stock, no par value per share (Title of Class of Securities) 00288U106 (CUSI |
|
| February 16, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* AbCellera Biologics Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 00288U 10 6 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 9, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. ) * AbCellera Biologics Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 00288U106 (CUSIP Number) December 31, 2020 (Date of Event Wh |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* AbCellera Biologics Inc. (Name of Issuer) Common shares, no par value per share (Title of Class of Securities) 00288U 10 6 (CUSIP Number) Tim Van Voris General Counsel Thiel Capital LLC 9200 Sunset Boulevard, Suite 1110 West Hollywood, CA 90069 323-990-20 |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* AbCellera Biologics Inc. (Name of Issuer) Common stock, no par value per share (Title of Class of Securities) 00288U106 (CUSI |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* AbCellera Biologics Inc. (Name of Issuer) Common stock, no par value per share (Title of Class of Securities) 00288U106 (CUSIP Number) December 1 |
|
| December 15, 2020 |
S-8 As filed with the Securities and Exchange Commission on December 14, 2020 Registration No. |
|
| December 14, 2020 |
24,150,000 Shares Common Shares 424B4 1 d29983d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-250838 and 333-251280 24,150,000 Shares Common Shares This is the initial public offering of common shares of AbCellera Biologics Inc. We are offering 24,150,000 of our common shares. Prior to this offering, there has been no public market for our common shares. The initial public offering price |
|
| December 10, 2020 |
As filed with the Securities and Exchange Commission on December 10, 2020. As filed with the Securities and Exchange Commission on December 10, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia 8731 Not Applicable (State or other jurisdiction of (Primary Standard |
|
| December 10, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on December 10, 2020. |
|
| December 8, 2020 |
8-A12B 1 d31585d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia Not Applicable (State of incorporation or organization) (I.R.S. Emp |
|
| December 8, 2020 |
CORRESP 1 filename1.htm December 8, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ada D. Sarmento Mary Beth Breslin Tara Harkins Lynn Dicker Re: AbCellera Biologics Inc. Registration Statement on Form S-1 (File No. 333-250838) Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations un |
|
| December 8, 2020 |
VIA EDGAR December 8, 2020 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street N. |
|
| December 7, 2020 |
EX-10.17 Exhibit 10.17 INDEMNIFICATION AGREEMENT THIS AGREEMENT is made as of this day of , 2020. B E T W E E N: AbCellera Biologics Inc., a corporation incorporated under the Business Corporations Act (British Columbia) (the “Company”) - and - [•] (the “Indemnified Party”) RECITALS: A. The Business Corporations Act (British Columbia) (the “BCBCA”) permits, and in some cases requires, the Company |
|
| December 7, 2020 |
EX-1.1 Exhibit 1.1 [●] AbCellera Biologics Inc. Common Shares UNDERWRITING AGREEMENT [●], 2020 CREDIT SUISSE SECURITIES (USA) LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED BERENBERG CAPITAL MARKETS LLC SVB LEERINK LLC BMO CAPITAL MARKETS CORP. As Representatives of the Several Underwriters c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010-3629 c/o Stifel, Nicolaus & |
|
| December 7, 2020 |
EX-3.3 Exhibit 3.3 TABLE OF CONTENTS BUSINESS CORPORATIONS ACT ARTICLES of ABCELLERA BIOLOGICS INC. Page ARTICLE 1 INTERPRETATION 1.1 Definitions 1 1.2 Business Corporations Act and Interpretation Act Definitions Applicable 1 ARTICLE 2 SHARES AND SHARE CERTIFICATES 2.1 Authorized Share Structure 2 2.2 Form of Share Certificate 2 2.3 Shareholder Entitled to Certificate or Acknowledgement 2 2.4 Deli |
|
| December 7, 2020 |
Notice of Articles of the Registrant as currently in effect EX-3.1 Exhibit 3.1 Location: Mailing Address: 2nd Floor - 940 Blanshard Street PO Box 9431 Stn Prov Govt Victoria BC Victoria BC V8W 9V3 1 877 526-1526 www.corporateonline.gov.bc.ca CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT CAROL PREST This Notice of Articles was issued by the Registrar on: December |
|
| December 7, 2020 |
EX-10.9 Exhibit 10.9 April 12, 2019 Private & Confidential By Electronic Mail Andrew Booth Dear Andrew: Re: Employment Agreement I am pleased to offer you a full time position as Chief Financial Officer at AbCellera Biologics Inc. (the “Company”). This letter agreement contains the complete terms and conditions of your employment with the Company (the “Agreement”). The terms of this agreement will |
|
| December 7, 2020 |
EX-10.8 Exhibit 10.8 August 1, 2019 Private & Confidential By Electronic Mail Dr. Carl Hansen Dear Carl: Re: Employment Agreement I am pleased to offer you a full-time position as Chief Executive Officer at AbCellera Biologics Inc. (the “Company”). This letter agreement contains the complete terms and conditions of your employment with the Company (the “Agreement”). The terms of this agreement wil |
|
| December 7, 2020 |
EX-4.2 Exhibit 4.2 PROOF PROOF PROOF PROOF PROOF PROOF PROOF NUMBER SHARES CS SEE REVERSE FOR INCORPORATED UNDER THE LAWS OF BRITISH COLUMBIA, CANADA CERTAIN DEFINITIONS C o M M o n s h a r e s CUSIP C4950N 10 8 This CerTifies ThaT: PROOF is The owner of FULLY PAID AND NON-ASSESSABLE SHARES WITHOUT PAR VALUE OF AbCellerA biologiCs inC. transferable on the books of the Corporation in person or by d |
|
| December 7, 2020 |
EX-10.13 Exhibit 10.13 ABCELLERA BIOLOGICS INC. 2020 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the AbCellera Biologics Inc. 2020 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of AbCellera Biologics Inc. (the “Company”) |
|
| December 7, 2020 |
EX-10.15 Exhibit 10.15 ABCELLERA BIOLOGICS INC. 2020 EMPLOYEE SHARE PURCHASE PLAN The purpose of the AbCellera Biologics Inc. 2020 Employee Share Purchase Plan (the “Plan”) is to provide eligible employees of AbCellera Biologics Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase common shares of the Company (the “Common Shares”). 2,700,000 |
|
| December 7, 2020 |
Articles of the Registrant as currently in effect EX-3.2 Exhibit 3.2 BUSINESS CORPORATIONS ACT BRITISH COLUMBIA ARTICLES ABCELLERA BIOLOGICS INC. BUSINESS CORPORATIONS ACT BRITISH COLUMBIA ARTICLES ABCELLERA BIOLOGICS INC. I N D E X PART 1 INTERPRETATION 1 PART 2 ALTERATIONS 3 PART 3 SHARES AND SHARE CERTIFICATES 4 PART 4 SHARE TRANSFERS 5 PART 5 PURCHASE OF SHARES 6 PART 6 BORROWING POWERS 6 PART 7 SHAREHOLDER MEETINGS 7 PART 8 PROCEEDINGS AT SH |
|
| December 7, 2020 |
EX-10.16 Exhibit 10.16 ABCELLERA BIOLOGICS INC. EXECUTIVE SEVERANCE PLAN 1. Purpose. AbCellera Biologics Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), considers it essential to the best interests of its shareholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, |
|
| December 7, 2020 |
EX-10.10 Exhibit 10.10 July 10, 2019 Private & Confidential By Electronic Mail Tryn T. Stimart, Esq. Dear Tryn: Re: Employment Agreement I am pleased to offer you a full-time position at Lineage Biosciences Inc. (“Lineage”), a wholly-owned US subsidiary of AbCellera Biologics Inc. (“AbCellera”) This letter agreement contains the complete terms and conditions of your employment with Lineage (the “A |
|
| December 7, 2020 |
EX-10.12 Exhibit 10.12 ABCELLERA BIOLOGICS INC. SIXTH AMENDED AND RESTATED STOCK OPTION PLAN Approved by the Board on November 18, 2020 Approved by the Shareholders on December 1, 2020 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND INTERPRETATION 1 1.1 Definitions 1 1.2 Choice of Law 4 1.3 Headings 4 ARTICLE 2 PURPOSE AND PARTICIPATION 4 2.1 Purpose 4 2.2 Participation 4 2.3 Notification of Award 5 2 |
|
| December 7, 2020 |
Power of Attorney for John Edward Hamer Amendment No. 2 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on December 7, 2020. Registration No. 333–250838 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbia |
|
| December 7, 2020 |
EX-10.11 Exhibit 10.11 Dec 20, 2016 Private & Confidential By Electronic Mail Véronique Lecault Dear Véronique: Re: Employment Agreement I am pleased to offer you full time employment with AbCellera Biologics Inc. (the “Company”). This letter agreement contains the complete terms and conditions of your employment with the Company (the “Agreement”). Your employment under this Agreement will start o |
|
| December 7, 2020 |
EX-10.14 Exhibit 10.14 ABCELLERA BIOLOGICS INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of AbCellera Biologics Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals |
|
| December 3, 2020 |
Goodwin Procter LLP 601 Marshall St, Redwood City, CA 94063 goodwinlaw.com +1 650 752 3100 December 3, 2020 VIA EDGAR AND FEDERAL EXPRESS Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Ada D. Sarmento Mary Beth Breslin Tara Harkins Lynn Dicker Re: AbCellera Biologics Inc. Registration Statement |
|
| November 30, 2020 |
Goodwin Procter LLP 601 Marshall Street Redwood City, CA 94063 goodwinlaw.com +1 650 752 3100 CONFIDENTIAL TREATMENT REQUESTED BY ABCELLERA BIOLOGICS INC. CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. OMITTED INFORMATION HAS BEEN REPLACED IN THIS LETTER A |
|
| November 25, 2020 |
Amendment No. 1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on November 24, 2020. Registration No. 333–250838 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AbCellera Biologics Inc. (Exact name of registrant as specified in its charter) British Columbi |
|
| November 20, 2020 |
EX-10.6 Exhibit 10.6 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and ABCELLERA BIOLOGICS INC. Table of Contents Article Page 1.0 DEFINITIONS 2 2.0 PROPERTY RIGHTS IN & TO THE TECHNOLOGY 7 3.0 GRANT OF LICE |
|
| November 20, 2020 |
EX-21.1 Exhibit 21.1 Subsidiaries of AbCellera Biologics Inc.* Name Jurisdiction of Incorporation or Organization AbCellera Properties Inc. Canada AbCellera Properties Columbia Inc. Canada AbCellera US Holdings Inc. Delaware Channel Biologics Pty Ltd. Australia Lineage Biosciences Inc. Delaware Trianni, Inc. California * Includes subsidiaries that do not fall under the definition of “significant s |
|
| November 20, 2020 |
EX-10.3 Exhibit 10.3 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer P |
|
| November 20, 2020 |
EX-10.5 Exhibit 10.5 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL S10-112 ● GSM, MW AMENDMENT 3/9/2017 AMENDMENT No 1 TO THE LICENSE AGREEMENT EFFECTIVE THE 11TH DAY OF FEBRUARY 2015 BETWEEN STANFORD UNIVERSITY AND LINEAGE BIOSCIENCES, INC. Effective the |
|
| November 20, 2020 |
EX-10.7 Exhibit 10.7 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. STRATEGIC INNOVATION FUND AbCellera COVID-19 Project This Agreement made Between: HER MAJESTY THE QUEEN IN RIGHT OF CANADA (“Her Majesty”) as represented by the Minister of Industry (the “Minister”) And |
|
| November 20, 2020 |
November 20, 2020 VIA EDGAR AND FEDERAL EXPRESS Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street N. |
|
| November 20, 2020 |
Articles of the Registrant as currently in effect EX-3.2 Exhibit 3.2 BUSINESS CORPORATIONS ACT BRITISH COLUMBIA ARTICLES ABCELLERA BIOLOGICS INC. BUSINESS CORPORATIONS ACT BRITISH COLUMBIA ARTICLES ABCELLERA BIOLOGICS INC. I N D E X PART 1 INTERPRETATION 1 PART 2 ALTERATIONS 3 PART 3 SHARES AND SHARE CERTIFICATES 4 PART 4 SHARE TRANSFERS 5 PART 5 PURCHASE OF SHARES 6 PART 6 BORROWING POWERS 6 PART 7 SHAREHOLDER MEETINGS 7 PART 8 PROCEEDINGS AT SH |
|
| November 20, 2020 |
EX-10.1 Exhibit 10.1 OFFICE PREMISES LEASE FROM: 0775021 BC Ltd. TO: AbCellera Biologics Inc. DATE OF LEASE: June 2, 2017 PROPERTY: 2215 Yukon Street, Vancouver, BC PREMISES: 20,996 square feet comprising 9,300 square feet on the first floor and 11,696 square feet on the second floor LEASE INDEX ARTICLE 1 BASIC TERMS, SCHEDULES, DEFINITIONS 1 1.01 Summary of Basic Terms 1 1.02 Definitions 3 1.03 S |
|
| November 20, 2020 |
EX-10.2 Exhibit 10.2 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL Execution Version RESEARCH COLLABORATION AND LICENSE AGREEMENT Between ABCELLERA BIOLOGICS INC. and ELI LILLY AND COMPANY RESEARCH COLLABORATION AND LICENSE AGREEMENT THIS RESEARCH COLLABOR |
|
| November 20, 2020 |
EX-99.1 Exhibit 99.1 Consent of Director Nominee AbCellera Biologics Inc. is filing a Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering of its common shares. In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being n |
|
| November 20, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on November 20, 2020. |
|
| November 20, 2020 |
EX-4.1 Exhibit 4.1 Execution Copy AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. CERTAIN DEFINITIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2. RESTRICTIONS ON TRANSFERABILITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
|
| November 20, 2020 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among ABCELLERA US HOLDINGS INC. and MICKEY MERGER INC. and TRIANNI, INC. and FORTIS ADVISORS LLC and, solely for the purpose of Section 10.03, ABCELLERA BIOLOGICS INC. dated as of November 1, 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 5 Section 1.01 Definitions 5 ARTICLE II THE MERGER 15 Section 2.01 The Merger 15 Section 2.02 Cl |
|
| November 20, 2020 |
EX-10.4 Exhibit 10.4 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXCLUSIVE (EQUITY) AGREEMENT This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (‘‘Stanford”), an institution of higher education having powers under the laws of the S |
|
| November 6, 2020 |
EX-21.1 Exhibit 21.1 Subsidiaries of AbCellera Biologics Inc.* Name Jurisdiction of Incorporation or Organization AbCellera Properties Inc. Canada AbCellera Properties Columbia Inc. Canada AbCellera US Holdings Inc. Delaware Channel Biologics Pty Ltd. Australia Lineage Biosciences Inc. Delaware Trianni, Inc. California * Includes subsidiaries that do not fall under the definition of “significant s |
|
| November 6, 2020 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among ABCELLERA US HOLDINGS INC. and MICKEY MERGER INC. and TRIANNI, INC. and FORTIS ADVISORS LLC and, solely for the purpose of Section 10.03, ABCELLERA BIOLOGICS INC. dated as of November 1, 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 5 Section 1.01 Definitions 5 ARTICLE II THE MERGER 15 Section 2.01 The Merger 15 Section 2.02 Cl |
|
| November 6, 2020 |
EX-10.3 Exhibit 10.3 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer P |
|
| November 6, 2020 |
RESEARCH COLLABORATION AND LICENSE AGREEMENT ABCELLERA BIOLOGICS INC. ELI LILLY AND COMPANY EX-10.2 Exhibit 10.2 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL Execution Version RESEARCH COLLABORATION AND LICENSE AGREEMENT Between ABCELLERA BIOLOGICS INC. and ELI LILLY AND COMPANY RESEARCH COLLABORATION AND LICENSE AGREEMENT THIS RESEARCH COLLABOR |
|
| November 6, 2020 |
BUSINESS CORPORATIONS ACT BRITISH COLUMBIA ABCELLERA BIOLOGICS INC. EX-3.2 Exhibit 3.2 BUSINESS CORPORATIONS ACT BRITISH COLUMBIA ARTICLES ABCELLERA BIOLOGICS INC. BUSINESS CORPORATIONS ACT BRITISH COLUMBIA ARTICLES ABCELLERA BIOLOGICS INC. I N D E X PART 1 INTERPRETATION 1 PART 2 ALTERATIONS 3 PART 3 SHARES AND SHARE CERTIFICATES 4 PART 4 SHARE TRANSFERS 5 PART 5 PURCHASE OF SHARES 6 PART 6 BORROWING POWERS 6 PART 7 SHAREHOLDER MEETINGS 7 PART 8 PROCEEDINGS AT SH |
|
| November 6, 2020 |
ABCELLERA BIOLOGICS INC. FIFTH AMENDED AND RESTATED STOCK OPTION PLAN EX-10.12 Exhibit 10.12 ABCELLERA BIOLOGICS INC. FIFTH AMENDED AND RESTATED STOCK OPTION PLAN Approved by the Board on March 23, 2020 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND INTERPRETATION 1 1.1 Definitions 1 1.2 Choice of Law 4 1.3 Headings 4 ARTICLE 2 PURPOSE AND PARTICIPATION 4 2.1 Purpose 4 2.2 Participation 4 2.3 Notification of Award 5 2.4 Copy of Plan 5 2.5 Limitation 5 ARTICLE 3 TERMS A |
|
| November 6, 2020 |
EX-10.6 Exhibit 10.6 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and ABCELLERA BIOLOGICS INC. Table of Contents Article Page 1.0 DEFINITIONS 2 2.0 PROPERTY RIGHTS IN & TO THE TECHNOLOGY 7 3.0 GRANT OF LICE |
|
| November 6, 2020 |
STRATEGIC INNOVATION FUND AbCellera COVID-19 Project EX-10.7 Exhibit 10.7 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. STRATEGIC INNOVATION FUND AbCellera COVID-19 Project This Agreement made Between: HER MAJESTY THE QUEEN IN RIGHT OF CANADA (“Her Majesty”) as represented by the Minister of Industry (the “Minister”) And |
|
| November 6, 2020 |
November 6, 2020 VIA EDGAR AND FEDERAL EXPRESS Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street N. |
|
| November 6, 2020 |
EX-10.5 Exhibit 10.5 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL S10-112 ● GSM, MW AMENDMENT 3/9/2017 AMENDMENT No 1 TO THE LICENSE AGREEMENT EFFECTIVE THE 11TH DAY OF FEBRUARY 2015 BETWEEN STANFORD UNIVERSITY AND LINEAGE BIOSCIENCES, INC. Effective the |
|
| November 6, 2020 |
Draft Registration Statement No. 2 Table of Contents As confidentially submitted to the Securities and Exchange Commission on November 6, 2020. This Amendment No. 1 to the draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration No. 333– UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing |
|
| November 6, 2020 |
EX-3.1 Exhibit 3.1 Location: Mailing Address: 2nd Floor - 940 Blanshard Street PO Box 9431 Stn Prov Govt Victoria BC Victoria BC V8W 9V3 1 877 526-1526 www.corporateonline.gov.bc.ca CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT CAROL PREST This Notice of Articles was issued by the Registrar on: November |
|
| November 6, 2020 |
EX-10.1 Exhibit 10.1 OFFICE PREMISES LEASE FROM: 0775021 BC Ltd. TO: AbCellera Biologics Inc. DATE OF LEASE: June 2, 2017 PROPERTY: 2215 Yukon Street, Vancouver, BC PREMISES: 20,996 square feet comprising 9,300 square feet on the first floor and 11,696 square feet on the second floor LEASE INDEX ARTICLE 1 BASIC TERMS, SCHEDULES, DEFINITIONS 1 1.01 Summary of Basic Terms 1 1.02 Definitions 3 1.03 S |
|
| November 6, 2020 |
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT EX-4.1 Exhibit 4.1 Execution Copy AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. CERTAIN DEFINITIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2. RESTRICTIONS ON TRANSFERABILITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
